₹966.95
+15.80 (+1.66%)
As of 23 Sept 2026, Remus Pharmaceuticals Ltd share price is ₹966.95. The stock opened at ₹966.95 and had closed at ₹951.15 the previous day. Over the last 52 weeks, the stock has recorded a low of ₹580.00 and a high of ₹1,007.00. In terms of performance, Remus Pharmaceuticals Ltd share price has increased by 40.52% over the past six months and has increased by 20.48% over the last year.
REMUS Stock Price Chart
Remus Pharmaceuticals Ltd Overview
Market cap₹1,121 Crs
Volume7,600
Prev. Close₹951.15
Year range₹580.00 - ₹1,007.00
ISININE0O5T01011
About REMUS
Remus Pharmaceuticals is engaged in marketing and distribution of pharmaceuticals products and allied products.
Remus Pharmaceuticals Ltd Historical Performance
1 Month Return-1.09%
6 Month Return56.75%
3 Year Return66.31%
3 Month Return21.44%
1 Year Return19.12%
5 Year Return-
Remus Pharmaceuticals Ltd Fundamentals
ROCE(TTM)10.19%
P/E Ratio (TTM)45.36
P/B Ratio3.44
Debt to Equity0.02
ROE7.59%
EPS (TTM)20.97
Dividend Yield0.05%
Book Value276.40
Profit Margin0.00%
Operating Margin0.00%
Remus Pharmaceuticals Ltd Financials
| Indicator | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Revenue | 100.83 | 82.07 | 66.75 | 46.61 | 25.44 |
| EBITDA | 36.56 | 28.89 | 23.81 | 12.12 | 4.85 |
| Net Profit | 24.71 | 19.90 | 16.62 | 8.50 | 3.43 |
| EPS | 20.96 | 33.75 | 29.40 | 83.24 | 34.34 |
Remus Pharmaceuticals Ltd Technical Analysis
| Indicator | Value |
|---|---|
| Support 1 (S1) | 928.10 |
| Resistance 1 (R1) | 988.10 |
| Pivot Point | 965.05 |
Remus Pharmaceuticals Ltd Dividend History
| Ex Date | Dividends Date | Record Date | Dividend Type | Dividend Details |
|---|---|---|---|---|
| 22-Sep-2026 | 20-May-2026 | 22-Sep-2026 | Final | ₹0.50 |
| 14-Nov-2025 | 10-Nov-2025 | 14-Nov-2025 | Interim 1 | ₹0.50 |
| 18-Sep-2025 | 17-May-2025 | 18-Sep-2025 | Final | ₹0.50 |
| 19-Nov-2024 | 09-Nov-2024 | 20-Nov-2024 | Interim | ₹1.00 |
| 02-May-2024 | 23-Apr-2024 | 02-May-2024 | Interim 2 | ₹4.00 |
REMUS Key Leadership Details
Last Updated: Mar 2025
| Name | Position |
|---|---|
| SWAPNIL JATINBHAI SHAH | Chairman |
| ARPIT DEEPAKKUMAR SHAH | Managing Director |
| Roma Vinodbhai Shah | Whole-time Directorector |
Remus Pharmaceuticals Ltd Peer Comparison
| Company | Price | M.Cap (Cr) | P/E (TTM) | ROE (TTM) |
|---|---|---|---|---|
| Sun Pharmaceutical Industries LtdSUNPHARMA | ₹1,852.40+0.32% | ₹4,19,727.66 | 38.32 | 13.74% |
| Divis Laboratories LtdDIVISLAB | ₹9,455.00+1.10% | ₹1,67,235.91 | 67.46 | 15.32% |
| Torrent Pharmaceuticals LtdTORNTPHARM | ₹4,936.50+0.03% | ₹1,46,951.32 | 64.68 | 25.49% |
Disclaimer
The information provided on this page is for informational purposes only and should not be construed as investment advice, recommendation, or solicitation to buy or sell any securities or financial pr...
Frequently Asked Questions
- The share price of Remus Pharmaceuticals Ltd today is ₹966.95 on NSE and ₹966.95 on BSE.
- The 52-week high of Remus Pharmaceuticals Ltd is ₹1,007.00, while the 52-week low is ₹580.00.
- The current market capitalisation of Remus Pharmaceuticals Ltd is approximately ₹1,121 crore.
- The P/E (Price-to-Earnings) ratio of Remus Pharmaceuticals Ltd is 18.28. The ratio may vary with changes in the share price and earnings.
- The P/B (Price-to-Book) ratio of Remus Pharmaceuticals Ltd is 2.74. It compares the company’s market value with its book value and can provide an indication of how the market values the company relative to its net assets.
- To buy Remus Pharmaceuticals Ltd shares, you first need to open a demat account before you can place an order. Here's the process:
• Open a demat account online using your PAN, Aadhaar and bank details.
• Add funds to your trading account via UPI or net banking.
• Search for REMUS on TradeMobi or the Anand Rathi web platform.
• Place your order
• Track your holdings in the portfolio section. - Over the past 3 years, Remus Pharmaceuticals Ltd has delivered a return of approximately 66.31%. This return is based on the change in the share price over the specified period and may differ depending on the measurement date. Past performance does not guarantee future returns.
- The shareholding pattern of Remus Pharmaceuticals Ltd comprises different categories of shareholders. As of Mar 2026, the shareholding is approximately 70.95% promoters, 5.28% FIIs, 0.83% DIIs, and 18.50% public shareholders.
Download TradeMobi App
- Real-Time Market Data
- Advanced Trading Tools
- Expert-Backed Research
